Results of OncoGenex phase I/II Custirsen trial published

Friday, January 6, 2012 09:32 AM

OncoGenex Pharmaceuticals has reported results of a phase I/II study to determine the effectiveness of its investigational compound custirsen in conjunction with a gemcitabine/platinum-based regimen in patients with advanced non-small cell lung cancer (NSCLC).

Results published in the January 2012 issue of the Journal of Thoracic Oncology showed the additional treatment of custirsen, designed to block production of tumor cell survival protein clusterin, improved survival rates by three to seven months longer than patients who adhered to only a gemcitabine/platinum-based regimen. The combination treatment produced a median overall survival of 14.1 months, and progression-free survival of 4.3 months. Moreover, the patients who achieved a threshold minimum of serum clusterin (</= 45mcg/mL) had a median survival of 27.1 months.

Additionally, the study determined the toxicity of the combination treatment was not appreciably different from that reported for a gemcitabine/platinum-based regimen on its own.

"The identification and targeting of new therapeutic pathways, such as clusterin inhibition, are required in order to improve outcomes for cancer patients," said Dr. Janessa Laskin, principal investigator on the study and a medical oncologist at the British Columbia Cancer Centre.

The single-arm trial, conducted at 15 sites in North America, consisted of 81 patients with untreated, advanced NSCLC. OncoGenex has entered a collaboration and license agreement for custirsen with Teva Pharmaceutical Industries. The companies are planning a randomized, phase III study of custirsen as a first-line treatment of advanced, unresectable non-small cell lung cancer.

Share:          
CWWeekly

March 2

Huntingdon Life Sciences-Harlan prepares for rebranding and U.S. expansion to compete with early phase CROs Covance, CRL

Patients' increased sharing of clinical trial experiences through social media can help sponsors improve outcomes, enrollment

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs